Status:
COMPLETED
RE-SEARCH Study: A Study to Learn How and in Which Amount Regorafenib is Given in Usual Practice to Patients in Spain: a Study Looking Back at Cases That Have Already Happened When the Study Begins.
Lead Sponsor:
Bayer
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Researchers are collecting more information to improve treatment of metastatic colorectal cancer (mCRC) with regorafenib. Metastatic colorectal cancer (mCRC) is a cancer that starts in the large bowe...
Eligibility Criteria
Inclusion
- Patient ≥ 18 years
- Patients with histological confirmation of mCRC
- Patient who started treatment with regorafenib for mCRC according to usual clinical practice during or after January 2017 and at least 3 months prior to the inclusion in the study
Exclusion
- Patient who have been treated with regorafenib during their participation in a clinical trial
Key Trial Info
Start Date :
July 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 7 2022
Estimated Enrollment :
242 Patients enrolled
Trial Details
Trial ID
NCT04920422
Start Date
July 15 2021
End Date
October 7 2022
Last Update
October 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations
Multiple Locations, Spain